Does low LH with low free and bioavailable testosterone indicate reduced pituitary stimulation of Leydig-cell testosterone production?

A comprehensive hormone evaluation for a 34-year-old male presenting with low free and bioavailable testosterone must distinguish between central signaling deficiencies and peripheral binding alterations.

Mechanistic explanations

• Pituitary-Leydig Axis Failure: Luteinizing Hormone (LH) is the primary endocrine signal secreted by the anterior pituitary that binds to receptors on testicular Leydig cells to stimulate testosterone synthesis. Low or inappropriately normal LH levels signal a central hypothalamic-pituitary deficiency rather than a primary testicular defect.
• Downstream Androgen Reduction: Deficient LH secretion directly diminishes Leydig cell stimulation, downregulating testicular testosterone output. This reduction in absolute synthesis consequently lowers both the total testosterone pool and its active free and bioavailable fractions.
• Distinct from Binding Variations: While changes in Sex Hormone-Binding Globulin (SHBG) alter testosterone availability—such as high SHBG decreasing free fractions, or low SHBG (common in insulin resistance) lowering total testosterone while sparing free levels—the concurrent depression of both LH and bioavailable testosterone points to an upstream signaling failure rather than isolated protein-binding shifts.

Bottom line

• The combination of low LH and low free/bioavailable testosterone confirms a diagnosis of secondary hypogonadism, indicating that reduced pituitary stimulation of Leydig cells is the root driver of androgen deficiency rather than isolated alterations in hormone-binding proteins.